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Abstract We investigated the effect of a chymase inhibitor Suc-
Val-Pro-PheP(OPh)2 on the proliferation of the grafted vein in
dog. By 28 days after the operation, the mean intimal area of the
grafted vein in the placebo group was 3.24 þ 0.32 mm2. The
intimal area of the grafted vein in the chymase inhibitor-treated
group was reduced to 63.9%. In the placebo group, the activities
of chymase and angiotensin-converting enzyme in grafted vein
were significantly increased 15- and 2-fold, respectively. In the
chymase inhibitor-treated group, chymase activity in the grafted
veins was decreased significantly. These findings suggest that
inhibition of chymase appears useful for preventing vascular
proliferation.
z 2000 Federation of European Biochemical Societies.
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1. Introduction
Vascular proliferation after vascular surgery and coronary
angioplasty has been thought to be dependent on an increase
of growth factors such as platelet-derived growth factor [1].
Angiotensin (ANG) II activates these growth factors, and
directly acts on extracellular signal-regulated kinase, which
leads to mitogenic or hypertrophic responses, resulting in in-
ducing the proliferation of vascular tissues [2,3]. In general, it
is known that ANG II is generated from ANG I by angio-
tensin-converting enzyme (ACE). However, in vascular tissues
in human, monkey, dog and hamster, chymase also converts
ANG I to ANG II [4^8]. On the other hand, vascular tissues
in rat and rabbit do not contain ANG II-forming chymases
[6]. Chymase hydrolyzes the C-terminal side of proteins after
aromatic amino acids such as Phe, Tyr and Trp. However,
using the substrate ANG I, human-type chymase cleaves the
Phe8-His9 bond of ANG I to yield the active substance ANG
II, while rat-type chymase cleaves the Tyr4-Ile5 bond of ANG
I to form inactive fragments [9,10].
ANG II produced from ANG I in vascular tissues is also
known to induce vascular contraction, but the conversion of
ANG I to ANG II is very di¡erent in various species. Vas-
cular contractions after injection of ANG I in isolated arteries
of rat were completely inhibited by an ACE inhibitor only,
suggesting that vascular tissues in rat contain ACE only as the
ANG II-forming enzyme. On the other hand, ANG I-induced
vascular contractions in human, monkey and dog were not
suppressed completely by an ACE inhibitor [6]. The remaining
contraction was suppressed by chymostatin, which inhibits
chymotrypsin-like enzymes including chymase, thus suggest-
ing that this remainder is due to chymase-dependent ANG II
formation. Thus, the chymase-dependent ANG II-forming
system has been shown by in vitro experiments, while that
of in vivo experiments has not as yet been clari¢ed because
there are no chymase inhibitors that are useful in in vivo
experiments.
In vascular proliferative responses of ANG II, an ACE
inhibitor was e¡ective in preventing the vascular proliferation
of post-balloon injury of vessels in rat [11]. Rat vascular tis-
sues contain ACE only as an ANG II-forming enzyme, and
this result suggests that vascular ANG II formation plays a
crucial role in tissue proliferation. Based on this report, it was
studied whether an ACE inhibitor suppresses human vascular
restenosis after percutaneous transluminal coronary angio-
plasty (PTCA), but the result was negative [12]. In grafted
vessels, an ACE inhibitor also prevented the vascular prolif-
eration in rat, but not in a baboon model [13,14]. Such species
di¡erences in the e¡ects of ACE inhibitors on the prolifera-
tion of vascular tissues may depend on whether or not a given
species possesses ANG II-forming chymase in vascular tissue.
Therefore, the chymase-dependent ANG II formation in vas-
cular tissue may be closely related to promoting growth in
vivo.
In this report, we investigated whether Suc-Val-Pro-
PheP(OPh)2, which inhibits strongly chymase activity [15],
could prevent vascular proliferation in grafted veins.
2. Materials and methods
2.1. Animal treatments
Ten dogs weighing 8 to 10 kg were obtained from Japan SLC
(Shizuoka, Japan), and were divided into two groups, a group treated
with chymase inhibitor, Suc-Val-Pro-PheP(OPh)2, and a vehicle
group. Each dog underwent right common carotid artery bypass
grafting with the ipsilateral external jugular vein. The animals were
anesthetized with sodium pentobarbital (35 mg/kg). In the placebo
group, the right external jugular vein was removed and was in¢ltrated
for 20 min in saline containing isosorbid dinitrate (50 mg/kg) and
dipyridamole (100 mg/kg), which were used as agents for vascular
dilation and antithrombosis, respectively. In the group treated with
the chymase inhibitor, the vein was in¢ltrated for 20 min in the so-
lution used for the placebo group, but with the addition of Suc-Val-
Pro-PheP(OPh)2 (10 WM). Then, the vein was grafted to the ipsilateral
artery. The experimental procedures for animals were in accordance
with the Guide for the Care and Use of Laboratory Animals (Animal
Research Laboratory, Osaka Medical College).
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2.2. Preparation of vascular tissue
At 28 days after the operation, the animals were anesthetized with
sodium pentobarbital (35 mg/kg), and then the grafted and the sym-
metrical veins were removed. We cut the tissue in half. One segment
was used for the measurement of the cross-sectional area, and the
other segment was used for assay of the ANG II-forming enzymes,
ACE and chymase. Immediately after excision, the tissues used for
histological analysis were formalin-¢xed, and the tissues used for the
determination of enzyme activity were frozen in liquid nitrogen. The
symmetrical carotid artery in the placebo-treated group was removed
and was used for the study of ANG I-induced vascular contraction.
2.3. Vascular contraction
The dog carotid arteries were cut into helical strips, 15 mm in
length and 2.0 mm in width. The strips from dog were placed on an
organ bath under a resting tension of 1.5 g in the bathing medium
[16]. The medium was continuously aerated with O2/CO2 (95:5),
which was maintained at 37‡C. The strip was equilibrated for 2 h
before the experiments of ANG I-induced contractile response. The
contractile response to 50 mM KCl was obtained ¢rst, and then the
bathing medium was washed out. The medium was washed out three
times for 20 min, each time with fresh Tyrode’s solution, and equil-
ibrated for 40 min. ANG I (¢nal concentration of 100 nM) was added
to the bathing medium. The steps for the ANG I-induced response
were repeated once again, and the second ANG I-induced response
was regarded as the control ANG I-induced response. After the re-
sponse, the medium was washed out three times for 20 min, each time
with fresh Tyrode’s solution. An ACE inhibitor, lisinopril (¢nal con-
centration of 1 WM), was added and preincubation was conducted for
20 min and then the ANG I-induced response was observed. In the
same manner, the ANG I-induced responses were observed after pre-
incubation for 20 min with a combination of 1 WM lisinopril, and
chymostatin or Suc-Val-Pro-PheP(OPh)2.
2.4. Histological analysis of vascular tissue
The vessel segments were ¢xed in 10% neutral bu¡ered formalin,
embedded in para⁄n and cut into 5-Wm thick sections. These sections
were stained with elastica-van Gieson, and the cross-sectional areas of
intima and media were quanti¢ed with an image analysis system (VM-
30, Olympus Optical Co., Tokyo, Japan).
2.5. Measurement of ACE and chymase activities
The vessels were homogenized in 10 volumes (w/v) of 20 mM Na-
phosphate bu¡er, pH 7.4. The homogenate was centrifuged at
20 000Ug for 30 min. The pellets were re-suspended and homogenized
in 5 volumes (w/v) of 10 mM Na-phosphate bu¡er, pH 7.4, containing
2 M KCl and 0.1% (v/v) Nonidet P-40. The homogenate was stored
overnight at 4‡C, and centrifuged at 20 000Ug for 30 min at 4‡C. The
supernatant was used for the measurements of ACE and chymase
activities. The ACE activity was measured using a synthetic substrate,
hippuryl-His-Leu (HHL), speci¢cally designed for ACE [17]. One unit
of ACE activity was de¢ned as the amount of enzyme that formed
1 Wmol hippuric acid/min. The chymase activity was measured by
incubating tissue extracts for 30 min at 37‡C with 770 WM ANG I
in 150 mM borax-borate bu¡er, pH 8.5, containing 8 mM dipyridyl,
770 WM DFP and 5 mM EDTA, as described previously [18]. The
enzyme reaction was terminated by addition of 15% (w/v) trichloro-
acetic acid. One unit of chymase activity was de¢ned as the amount of
enzyme that formed 1 Wmol ANG II/min.
2.6. Statistical analysis
All experiments were done with ¢ve dogs per group. Statistical
analysis was done using ANOVA followed by a Student’s t-test. Val-
ues of P6 0.05 were considered signi¢cant. Data are expressed as
mean þ standard error of the mean (S.E.M.).
3. Results
Fig. 1 shows the e¡ects of chymostatin and Suc-Val-Pro-
PheP(OPh)2 on the vascular contractions induced by 100 nM
ANG I in the presence of an ACE inhibitor in the isolated
dog vascular tissues. Suc-Val-Pro-PheP(OPh)2 suppressed the
ANG I-induced vascular contraction in isolated dog arteries
in the presence of an ACE inhibitor. The IC50 values of chy-
mostatin and Suc-Val-Pro-PheP(OPh)2 in dog artery were 97
nM and 2.8 nM, respectively.
The intimal formation of the grafted veins in the placebo
group was developed from 14 days and was completely
formed at 28 days, and we decided on investigating the vessels
28 days after the operation (data not shown). As shown in
Fig. 2 as typical sections, the chymase inhibitor suppressed the
area of intima. The areas of intima and media from the
grafted and symmetrical veins treated with placebo or the
chymase inhibitor are shown in Table 1. In the placebo group,
the intimal area of the grafted vein was 3.24 þ 0.32 mm2, but
that of the symmetrical vein was hardly measured. The mean
intimal area of the grafted veins in the placebo group was
regarded as 100%, while that in the group treated with chy-
mase inhibitor was reduced to 63.9%.
In the placebo group, the chymase activity in the grafted
veins was increased signi¢cantly when compared with that in
the symmetrical veins (the grafted veins vs. the symmetrical
veins: 12.4 þ 1.10 vs. 0.82 þ 0.15 mU/mg protein) (Fig. 3). The
ACE activities in the grafted and symmetrical veins were
4.46 þ 0.58 and 2.16 þ 0.26 mU/mg protein, respectively, and
this di¡erence was also signi¢cant (Fig. 3). In the chymase
inhibitor-treated group, the chymase activity was 5.73 þ 1.17
mU/mg protein and was decreased signi¢cantly compared to
the levels of the grafted veins in the placebo group (Fig. 4).
The ACE activities in the grafted veins were not a¡ected by
treatment with the chymase inhibitor (Fig. 4).
4. Discussion
In the present study, we demonstrated for the ¢rst time that
a chymase inhibitor suppressed vascular proliferation in
grafted veins in dog, suggesting that the chymase-dependent
ANG II-forming system has an important role in vascular
Fig. 1. E¡ects of chymostatin (a) and Suc-Val-Pro-PheP(OPh)2 (b)
on the contraction induced by 100 nM ANG I in the presence of
1 WM lisinopril in the isolated dog carotid arteries (N = 5).
Table 1
The areas of intima and media in the placebo- and chymase inhibi-
tor-treated groups
Group Area (mm2)
Intima Media
Placebo 3.24 þ 0.32 3.43 þ 0.39
Chymase inhibitor 1.17 þ 0.21* 3.26 þ 0.36
Values represent the mean þ S.E.M. (N = 5).
*P6 0.001 vs. the placebo-treated group.
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proliferation in vivo. Previously, Oleksyszyn and Powers [15]
reported that Suc-Val-Pro-PheP(OPh)2 is a speci¢c chymase
inhibitor and the half-degradative time is about 20 h in hu-
man plasma. Suc-Val-Pro-PheP(OPh)2 suppressed the ANG I-
induced vascular contraction in isolated dog arteries in the
presence of an ACE inhibitor, thus indicating a chymase-de-
pendent ANG II formation (Fig. 1). The IC50 value of Suc-
Val-Pro-PheP(OPh)2 in dog artery was 2.8 nM. The IC50 value
of Suc-Val-Pro-PheP(OPh)2 was about 35 times larger than
that of chymostatin, which is typical of a compound that
inhibits chymase [4^8]. These ¢ndings suggest that Suc-Val-
Pro-PheP(OPh)2 may be a stable and strong chymase inhibitor
in vivo; however, because the inhibitor cannot be orally ad-
ministered, it has been thought that the compound could not
Fig. 3. ACE and chymase activities of the symmetrical veins and
grafted veins from dogs treated with placebo. Each bar represents
the mean þ S.E.M. (N = 5). **P6 0.01 and ***P6 0.001 vs. the sym-
metrical veins.
Fig. 2. Histological cross-sections stained with elastica-van Gieson of the grafted vein (A) from the dog treated with placebo, and of the grafted
vein (B) from the group treated with Suc-Val-Pro-PheP(OPh)2. I, intima. Bar, 1 mm. These sections are representative of the ¢ndings summa-
rized in Table 1.
Fig. 4. E¡ects of Suc-Val-Pro-PheP(OPh)2 on ACE activity and chy-
mase activity of the grafted veins from dogs treated with placebo or
Suc-Val-Pro-PheP(OPh)2. Each bar represents the mean þ S.E.M.
(N = 5). ***P6 0.001 vs. the placebo group.
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be used in vivo. In the present study, we demonstrated that
local in¢ltration, and not oral administration, of Suc-Val-Pro-
PheP(OPh)2 (10 WM) could prevent vascular proliferation in
grafted veins.
Clinically, stenosis of the coronary arteries is primarily
treated by intracoronary therapies such as PTCA or by sur-
gical therapies such as grafts of arteries or veins. Previously,
in dog, which has the chymase-dependent ANG II-forming
pathway, the activities of both ACE and chymase in arteries
injured by a balloon catheter were increased compared with
those in uninjured arteries ; an ANG II type 1 receptor antag-
onist was e¡ective in preventing intimal formation of vessels
after injury, but an ACE inhibitor was ine¡ective [19]. These
¢ndings suggest that the chymase-dependent ANG II-forming
system may be closely related to promoting the growth of
vascular tissues, while the role in the chymase-dependent
ANG II-forming system could not be investigated, because
there are no chymase inhibitors that are useful in vivo. In
the present model, the chymase and ACE activities in the
grafted veins were increased 15- and 2-fold, respectively,
whereas treatment with the chymase inhibitor signi¢cantly
decreased the chymase activity, but not the ACE activity.
From the relation between the pathogenesis and the activities
of these ANG II-forming enzymes, the chymase-dependent
ANG II formation may be more important for stenosis than
the ACE-dependent ANG II formation. In fact, treatment
with the chymase inhibitor only suppressed the development
of the intimal formation in this model.
The chymase inhibitor was used only during the operation
and not continuously, but it suppressed the intimal formation
of the grafted vein even 28 days after the operation. Clinically,
the veins for grafting are in¢ltrated with the agents for vas-
cular dilation and antithrombosis. In the present study, we
only added the chymase inhibitor into the solution, and this
method may be useful easily in clinical study. However, it is
interesting that the chymase inhibitor, applied to the grafted
vein only once after the operation, inhibited the chymase ac-
tivity even 28 days after the operation. It is reported that
chymase, an enzyme that is present in mast cell granules, is
released from the granules upon strong stimulation, binds to
extracellular matrix, and continues to function for several
weeks [20^22]. In this study, mast cells derived from the
grafted vessels were activated 1 day after the operation (un-
published data), indicating that chymase was bound to the
extracellular matrix immediately after the operation, and
thereby continued to function for several weeks. The chymase
inhibitor used in this study functions irreversibly, which
means that the inhibitor, once bound to the enzyme, continues
to inhibit it for a long time. In fact, up to 7 days after the
operation, the chymase activity was completely inhibited by
treatment with the chymase inhibitor (unpublished data). It is
thought that the inhibitor was irreversibly bound to the chy-
mase that was released upon degranulation immediately after
the operation, which then bound to the extracellular matrix,
resulting in the inhibition of chymase for several weeks. This
may be the reason why chymase activity remained inhibited
even 28 days after the operation. Moreover, chymase is
known to activate stem cell factor, a typical cytokine that
has the ability to induce accumulation of mast cells [23]. In
this study, the chymase inhibitor may also suppress the accu-
mulation of mast cells, resulting in the inhibition of chymase
28 days after the operation.
In conclusion, chymase plays an important role in vascular
proliferation in vivo, and thus inhibition of chymase may be
useful for preventing vascular diseases such as vascular pro-
liferation in grafted vessels.
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